Studies sleep, breathing and thinking skills in young people with sickle cell disease
Observes sleep breathing and thinking skills in people with sickle cell disease.
Key facts
- Who runs it
- St. Jude Children's Research Hospital
- Where
- Memphis, United StatesSee the site
- Trial code
- Registry title
- Peripheral Arterial Tonometry and Neurocognition in Sickle Cell Disease
- Status
- Recruiting
- People taking part
- 65 people, planned
- Started
- 16 Sept 2024
- Expected to end
- Jun 2028
- Type of study
- Observational
- Record updated
- 29 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for young people aged 12 to 25 with sickle cell disease of any genotype. It studies sleep, breathing at night and thinking skills.
- Age
- 12 to 25 years
- Sex
- All sexes can join.
- Disease stage
- Sickle cell disease of any genotype.
- Earlier treatment
- People cannot join if they are having treatment meant to remove all of the sickle cell disease (stem cell transplant or gene therapy). People cannot join if they are currently prescribed an intervention for a sleep disorder.
Main reasons for not taking part
- History of an intellectual disability
- History of a traumatic brain injury or seizure disorder
- History of a stroke
- Undergoing stem cell transplant or gene therapy for sickle cell disease
- Currently prescribed an intervention for a sleep disorder
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Diagnosed with sickle cell disease of any genotype
- Participant in the Sickle Cell Clinical Research and Intervention Program
- Between 12-25 years of age at the time of enrollment
- English is the primary language
- Access to an electronic device with WiFi
Who cannot take part
- Undergoing potential curative treatment for SCD (stem cell transplant or gene therapy)
- History of an intellectual disability
- History of a traumatic brain injury or seizure disorder
- History of a stroke
- Currently prescribed an intervention for a sleep disorder
- Inability or unwillingness of research participant or legal guardian/representative to give written informed consent
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 25 years old?
Where in United States
- St. Jude Children's Research HospitalMemphis, United StatesContact: Andrew Heitzer, PhDTaking people
About the trial
What the trial wants to find out
This study will examine sleep disordered breathing and sleep quality in participants (ages 12-25) diagnosed with sickle cell disease of any genotype. We will utilize remote peripheral arterial tonometry (PAT) and questionnaires to evaluate difficulties with sleep. PAT assessments will occur remotely in the homes of participants.
Read full original descriptionShow less
Neurocognitive, behavioral, and neuroimaging evaluations will occur on the same day as a routine clinic visit.
Primary Objective:
Evaluate the relationship between nocturnal oxyhemoglobin saturation (SpO2) and neurocognitive functioning (working memory and verbal comprehension) in individuals (ages 12-25) diagnosed with sickle cell disease controlling for age, genotype, and social vulnerability.
Secondary Objective:
Assess differences in white matter integrity, silent cerebral infarcts, neuroinflammation, and functional connectivity among individuals (ages 12-25) diagnosed with sickle cell disease with and without sleep disordered breathing after controlling for age.
Assess differences in self- and caregiver-reported mood and pain severity among individuals (ages 12-25) diagnosed with sickle cell disease with and without sleep disordered breathing after controlling for age.
Exploratory Objectives:
Explore the relationship between nocturnal oxyhemoglobin saturation (SpO2) and neurocognitive functioning (attention, processing speed, verbal memory, visual memory, motor dexterity) in individuals (ages 12-25) diagnosed with sickle cell disease controlling for age, genotype, and social vulnerability.
Assess the feasibility of an optical imaging tool (Speckle Contrast Optical Spectroscopy - Open-Motion 3.0) to measure cerebral blood flow and blood volume in patients diagnosed with sickle cell disease (ages 12-25).
Assess the concordance between measurement of cerebral blood flow and volume using speckle contrast optical spectroscopy and arterial spin labeling brain MRI.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Peripheral Arterial Tonometry and Neurocognition in Sickle Cell Disease
- Plain-language title
- Studies sleep, breathing and thinking skills in young people with sickle cell diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06477289, who can take part
- Record updated
- 29 June 2026